165 related articles for article (PubMed ID: 17911433)
1. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.
Ross CJ; Carleton B; Warn DG; Stenton SB; Rassekh SR; Hayden MR
Ann N Y Acad Sci; 2007 Sep; 1110():177-92. PubMed ID: 17911433
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and its implications for autoimmune disease.
Ross CJ; Katzov H; Carleton B; Hayden MR
J Autoimmun; 2007; 28(2-3):122-8. PubMed ID: 17418528
[TBL] [Abstract][Full Text] [Related]
3. Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
Wong E; Carleton BC; Wright DF; Smith MA; Verbeek L; Hildebrand CA; Stannard P; Vaillancourt R; Elliot-Miller P; Ross CJ; Hayden MR
Stud Health Technol Inform; 2009; 143():209-14. PubMed ID: 19380938
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
Carleton B; Poole R; Smith M; Leeder J; Ghannadan R; Ross C; Phillips M; Hayden M
Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):713-21. PubMed ID: 19507171
[TBL] [Abstract][Full Text] [Related]
5. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
[TBL] [Abstract][Full Text] [Related]
7. Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC; Smith MA; Gelin MN; Heathcote SC
Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenomics: the quest for individualized therapy].
López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
[TBL] [Abstract][Full Text] [Related]
9. Public involvement in pharmacogenomics research: a national survey on public attitudes towards pharmacogenomics research and the willingness to donate DNA samples to a DNA bank in Japan.
Kobayashi E; Satoh N
Cell Tissue Bank; 2009 Nov; 10(4):281-91. PubMed ID: 19629751
[TBL] [Abstract][Full Text] [Related]
10. Ontogeny and drug metabolism in newborns.
Dotta A; Chukhlantseva N
J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley.
Jha N; Bajracharya O; Namgyal T
Kathmandu Univ Med J (KUMJ); 2007; 5(4):504-10. PubMed ID: 18604084
[TBL] [Abstract][Full Text] [Related]
12. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
Taras-Zasowski KM; Einarson TR
Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
[TBL] [Abstract][Full Text] [Related]
13. Preventing adverse drug reactions in the general population.
Pezalla E
Manag Care Interface; 2005 Oct; 18(10):49-52. PubMed ID: 16265935
[TBL] [Abstract][Full Text] [Related]
14. New ways to detect adverse drug reactions in pediatrics.
Rieder M
Pediatr Clin North Am; 2012 Oct; 59(5):1071-92. PubMed ID: 23036245
[TBL] [Abstract][Full Text] [Related]
15. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics: state of the research and perspectives in clinical application.
Severino G; Chillotti C; Stochino ME; Del Zompo M
Neurol Sci; 2003 May; 24 Suppl 2():S146-8. PubMed ID: 12811615
[TBL] [Abstract][Full Text] [Related]
17. Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database.
Tanoshima R; Khan A; Biala AK; Trueman JN; Drögemöller BI; Wright GEB; Hasbullah JS; Groeneweg GSS; Ross CJD; Carleton BC;
J Clin Pharmacol; 2019 Mar; 59(3):356-363. PubMed ID: 30452777
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
19. [Can the screening of blood samples identify adverse drug reactions?].
Buajordet I; Laake K; Brørs O
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1637-9. PubMed ID: 17571101
[TBL] [Abstract][Full Text] [Related]
20. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety.
Beitelshees AL; McLeod HL
Trends Pharmacol Sci; 2006 Sep; 27(9):498-502. PubMed ID: 16876261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
